Skip to main content
All lobbying filings

CENCORA, INC.

Lobbying for CENCORA, INC.

 Filing 3rd Quarter - Report
Reporting period
3rd Quarter 2025
July 1 - Sep 30 · Posted Oct 20, 2025
Expenses
$680,000.00
What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 6
  • Centers For Medicare and Medicaid Services (CMS)
  • Food & Drug Administration (FDA)
  • Health & Human Services, Dept of (HHS)
  • HOUSE OF REPRESENTATIVES
  • SENATE
  • White House Office

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Bills named in this filing 7
  • HR 1
    An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
  • HR 3164
    Ensuring Community Access to Pharmacist Services Act
  • S 2426
    Equitable Community Access to Pharmacist Services Act
  • HR 4132
    Prescription Information Modernization Act of 2025
  • S 2027
    Prescription Information Modernization Act of 2025
  • HR 2483
    SUPPORT for Patients and Communities Reauthorization Act of 2025
  • S 2121
    SUPPORT for Patients and Communities Reauthorization Act of 2025
 Lobbying activity 4
Taxation/Internal Revenue Code

One Big Beautiful Bill Act/Budget Reconciliation (H.R.1) Tariff proposed policies LIFO accounting method Global Intangible Low-taxed Income (GILTI)

Medicare/Medicaid

Ensuring Community Access to Pharmacist Services Act (H.R. 3164)/Equitable Community Access to Pharmacist Services Act (S.2426) Inflation Reduction Act implementation, including impact on Pharmacy & Physician Reimbursement Extend payment increase under Medicare's physician fee schedule. Medicare Access & CHIP Reauthorization Act (MACRA). CMS Proposed Medicare Physician Fee Schedule Rule Protecting Patient Access to Cancer and Complex Therapies Act 2025 Reimbursement policies impacting drug shortages Part B drug pricing changes Enhanced Oncology Model (EOM) Preventing and Mitigating Generic Drug Shortages

Pharmacy

Preventing and Mitigating Generic Drug Shortages Ensuring Seniors Access to Critical Medications Act (H.R. 3164)/Equitable Community Access to Pharmacist Services Act (S.2426)- Impacts to pharmacy Part D drug pricing in Inflation Reduction Act (IRA)

Health Issues

Strategic National Stockpile. Essential Medicines Strategic Stockpile Prescription Information Modernization Act (H.R.4132/S.2027) Mitigation of Drug Shortages Pandemic and All Hazards Preparedness Reauthorization and Response Act (legislation). SUPPORT for Patients and Communities Reauthorization Act of 2025 (H.R. 2483/S.2121) Medical Supply Resiliency Act National Defense Authorization Act FY2026 (NDAA) Supply Chain Resiliency Most Favored Nation drug pricing proposals One Big Beautiful Bill Act / Budget Reconciliation (H.R.1) CMS Proposed Medicare Physician Fee Schedule Rule

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem